Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased net loss and reduced cash reserves.

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Zymeworks (NYSE:ZYME – Free Report) had its target price raised by Citigroup from $18.00 to $19.00 in a report released on ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session.

Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

Zymeworks (NYSE:ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a 10% holder and board member, EcoR1 made several purchases in December and ...